CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Mira is helping fill the hormone knowledge gap for women and the medical industry

From TechCrunch

By Unknown

September 10, 2024

Mira is helping fill the hormone knowledge gap for women and the medical industry

Mira is helping fill the hormone knowledge gap for women and the medical industry

Hormones play a massive role in when and how easily women can get pregnant, but research and resources in this area are lacking. Mira is looking to change that.

Mira is an at-home, palm-sized hormone testing device women use to test their urine for their hormone levels. Mira’s corresponding app deciphers their results and spots patterns which help women better plan for the right time to try to get pregnant or know when it’s time to bring up potential issues with their doctor.

Sylvia Kang, the co-founder and CEO of Mira, said on a recent episode of TechCrunch’s Found podcast that she was inspired to launch the company because she thought there should be a better way for women to plan fertility that wasn’t just an ovulation tester, which tests if you are currently ovulating, or costly IVF. Kang got further conviction when she realized how little the medical industry knew about the space.

“There were so many activity trackers, like a Fitbit for your general health, and also we’re already sending people to moon, you know, it’s the 21st century, but the female hormone tracking and the fertility understanding was still really, really lacking,” Kang said.

Kang said she decided to make Mira an at-home testing device because when she launched Mira in 2017, it was the peak two trends: building internet-of-thing devices and direct-to-consumer products.

When she launched, many investors struggled to get it. Kang said that if an investor had experienced fertility issues themselves or through a partner, they understood it, but if they hadn’t, this issue just didn’t make sense to them.

“Our consumer, you know, the education is there,” Kang said on women understanding their hormonal cycle. ” We could understand our data. Just like you go to see a doctor, you should own your test results. You should understand what’s happening so I can control my body. And so that was the the goal and was kind of like a driving force behind this.”

Kang said that Mira’s future will go beyond just being an IoT consumer device company. The company tracks and anonymizes every users’ results which means it’s building up a database of information on women’s health that could potentially fill the data void that helped inspire the company.

“This will really drive women’s health to the new level,” Kang said. “It’s not just like, oh, consumers tracking this at home, and then they just, it’s good to know. It’s not just good to know. It’s what you must have, what you must understand. So we’re actively working on that and this.”

View original article on techcrunch.com

Most Recent

Neocloud operator Nscale’s IPO plans could be at risk after Microsoft cancels UK data center project

British neocloud startup Nscale Global Holdings Ltd.’s plans to launch an initial public offering in the U.S. have suffered a massive setback after its biggest customer Microsoft Corp. pulled out of a critical data center deal this weekend. A report in The Telegraph on Sunday said Microsoft has term

Oct 18, 2026

Disney agrees to hire the majority of Character.AI’s workforce

After chatbot startup Character.AI filed for bankruptcy earlier this week, many of its employees will have the opportunity to take jobs at Disney.

Oct 18, 2026

Reflection AI open-sources Beam’s weights, post-training recipes

Startup Reflection AI Inc. today made the weights of Beam, its first large language model, available on Hugging Face. The company also released technical resources that will enable developers to customize the algorithm. Originally introduced last week, Beam is one of the industry’s most advanced ope

Oct 16, 2026

What to expect during Dell’s ‘Cyber Resilience’ event: Join theCUBE Oct. 27

Data protection and cyber recovery are foundational to enterprise AI. See how Dell is rethinking resilience at the theCUBE's Oct. 27 summit.

Oct 16, 2026

Similar Posts

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health provides medical support for women’s brain health, a voice-first, AI-powered companion that helps women in their 30s to 50s navigate the hormonal changes that affect brain health.

Oct 1, 2025

Peanut, a social network for women, adds a pregnancy tracking tool

Peanut, a social networking app for women, is launching a new feature to help users track their pregnancies. The new Peanut Track tool leverages seven years of data from questions asked on the social network and uses AI to anticipate questions that women have during different stages of their pregnancy. Founded in 2017, Peanut is an online community that is designed to connect women throughout all stages of their lives, from puberty to menopause. Now, the company is giving women personalized an

Oct 14, 2024

Startup Evvy raises $40M to accelerate precision diagnostics and medicine for women’s health

Evvy, an artificial intelligence startup that’s looking to enhance women’s healthcare, said today it has closed on $40 million in Series B funding to scale its precision diagnostics and care platform. The round was led by Catalio Capital Management, with new investors including the U.S. Fertility In

Sep 15, 2026

Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

Inito, a YC alum that helps women track fertility hormones quickly at home, has raised $6 million in Series A funding led by Fireside Ventures. The startup’s fertility monitor and kit is designed to give users easy-to-read fertility diagnostic results directly on their phone in just 10 minutes. The Bengaluru, India-based startup was founded in […]

Nov 15, 2023